收费全文 | 495篇 |
免费 | 35篇 |
耳鼻咽喉 | 11篇 |
儿科学 | 35篇 |
妇产科学 | 2篇 |
基础医学 | 86篇 |
口腔科学 | 14篇 |
临床医学 | 37篇 |
内科学 | 94篇 |
皮肤病学 | 3篇 |
神经病学 | 30篇 |
特种医学 | 11篇 |
外科学 | 29篇 |
综合类 | 9篇 |
预防医学 | 24篇 |
眼科学 | 34篇 |
药学 | 40篇 |
中国医学 | 3篇 |
肿瘤学 | 68篇 |
2023年 | 6篇 |
2022年 | 3篇 |
2021年 | 19篇 |
2020年 | 25篇 |
2019年 | 15篇 |
2018年 | 28篇 |
2017年 | 14篇 |
2016年 | 10篇 |
2015年 | 14篇 |
2014年 | 22篇 |
2013年 | 27篇 |
2012年 | 32篇 |
2011年 | 30篇 |
2010年 | 16篇 |
2009年 | 16篇 |
2008年 | 33篇 |
2007年 | 21篇 |
2006年 | 17篇 |
2005年 | 24篇 |
2004年 | 15篇 |
2003年 | 19篇 |
2002年 | 18篇 |
2001年 | 11篇 |
2000年 | 12篇 |
1999年 | 8篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 7篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1976年 | 4篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
Methods: Electronic databases were searched for randomized controlled trials, cohort studies and conference abstracts for studies comparing a SUP agent in critically ill patients to another active SUP agent or placebo. Overt, occult and clinically significant upper gastro-intestinal (UGI) bleeding, all-cause mortality, pneumonia, gastric colonization and ICU length of stay were considered as the outcome measures. A random effects model was used to generate pooled estimates.
Results: A total of 53 studies (4258 participants) were included. The pooled estimates were in favor of PPI and sucralfate for the overt UGI bleeding. PPI and H2RA bolus were associated with increased risk of gastric colonization and pneumonia.
Conclusions: SUP in critically ill patients was not associated with any benefit with regard to clinically significant bleeding episodes. However, PPI and sucralfate significantly reduces overt UGI bleeding. On the contrary, PPI and H2RA bolus are associated with an increased risk of gastric colonization and pneumonia. 相似文献
Methods: Electronic databases were searched for appropriate randomized clinical trials comparing iron chelators in patients with iron overload. Random effects model was used to generate direct, indirect and mixed treatment comparison pooled estimates for the following outcomes: serum ferritin, liver iron concentration (LIC), changes in serum ferritin, mortality, urine iron excretion, adverse events, neutropenia, agranulocytosis and number of patients withdrawing the chelating therapy.
Results: Thirty-two clinical trials were included in the meta-analysis. DFX/DFO was associated with better serum ferritin levels compared to DFO, DFX, DFO/Silymarin and DFP/DFO. DFX/DFO also lower LIC significantly compared to DFO. DFP/DFO was associated with higher LVEF, low risk of adverse events and reduced end of serum ferritin compared to DFO. Combination of silymarin with either DFP or DFX was observed with reduced end of treatment serum ferritin compared to using either of the drugs alone. DFP was observed with better effects in sickle cell disease. The strength of evidence was very low for most of the comparisons.
Conclusion: Relative estimates between the individual iron chelators have been established. However, this evidence should be considered preliminary and may change with the results of future head-to-head clinical trials. 相似文献